Type IV pili (T4P) are major virulence factors of Pseudomonas aeruginosa (P. aeruginosa) that are associated with primary adhesion, biofilm formation and twitching motility. This study focuses on the introduction of a novel biologically active subunit vaccine derived from the disulfide loop (DSL) of P. aeruginosa pilin. We investigated the expression of the novel PilA in-frame with pET26b vector, which contains three domains, that each domain contains three tandem repeats. The flexible (GGGGS) and (GGGGS)3 linkers were linked between the three tandem repeats and each pilA domain, respectively. The recombinant construct (pET26b/pilA) was transformed and expressed in Escherichia coli BL21 (DE3). The reactivity of specific antiserum against PilA was assessed by ELISA method. The biological activities of this candidate vaccine were evaluated by western blotting, opsonophagocytosis and twitching inhibition assays. The pET26b/pilA plasmid was confirmed by enzymatic digestion. The purified PilA protein was confirmed by immunoblot analysis. The checkerboard titration showed that the optimal dilution of the antibody to react with antigen was 1:8. The results of opsonophagocytosis assay revealed that the antibodies raised against PilA promoted phagocytosis of the PAO1 and 6266E strains to some extent (17.5% and 16.3%, respectively), so the twitching inhibition test confirmed this result. Taken together, these are the preliminary results based on a first chimerical structure failure to induce antibodies that promote the opsonization and eradication of the pathogen. Therefore, the biological activity of the PilA protein showed that it should be introduced with other proteins or target antigens against P. aeruginosa in the future studies.
he bacterium Pseudomonas aeruginosa (P. aeruginosa) is a ubiquitous organism that is also known as an opportunistic human pathogen, causing both chronic and acute infections in susceptible populations, including individuals with burn wounds or cystic fibrosis, or intensive care unit patients (1) . P. aeruginosa can infect almost any part of the human body, but typically targets surface-exposed epithelial cells, such as in the skin, airways and eyes. The most important question that still remains unanswered for non-obligate pathogens like P. aeruginosa is how these bacteria initiate infections after entering the host. Given that P. aeruginosa is among the many bacteria that grow as a biofilm during infection, there is a need to understand how this bacterium attaches to individual cells and form biofilm following surface colonization.
The pathogenesis of P. aeruginosa infections is multifactorial and includes a complex of virulence factors; hence, it has made vaccine development difficult. Bacterial attachment is an initial and a critical step for the establishment of infection that involves bacterial adhesion and host receptors. One of the most important adhesins in P. aeruginosa is pili (2) . Type IV pili (T4P) are thin, long, flexible, and retractable protein filaments.
T4P are polarly localized; filamentous surface appendages present at the cell surface of a broad range of pathogenic and environmental bacterial species (3) . T4P have an average length of 2.5 μm and is 5.2 nm in outer diameter and 1.2 nm in central channel diameter (4) . This adhesive cellsurface structures are the prominent virulence factors that are essential for the initiation of infection by mediating attachment to host cells, whereas non-piliated strains were reported to show a 90% decrease in their ability to bind human pneumocytes (5) , and also mutant strains that are unable to produce T4P are attenuated in virulence (6, 7) . Furthermore, another study revealed that non-piliated strains caused 28%-96% fewer cases of P. aeruginosa pneumonia as compared to piliated strains in a mouse model of infection (8) .
T4P plays an important role in many processes, including attachment to biotic and abiotic surfaces, DNA uptake, biofilm formation, phage transduction and a special form of bacterial cell movement, known as 'twitching motility' (9) , hence, they have been used as an ideal target antigen for vaccine development.
T4P have been classified into two different subtypes, type IVa pilus (T4aP) and type IVb pilus (T4bP), based on differences in the architecture of the assembly systems and in the structure of the major pilin subunit. T4aP is found in a wide variety of bacterial species such as P. aeruginosa, whereas T4bP is found predominantly in enteric pathogens (3) . The pilus fiber is composed of thousands of copies of PilA (or pilin, the major structural subunit) that are encoded by an operon that is positively controlled by the algR regulator (10).
The PilA monomer can be divided into three regions: a highly conserved hydrophobic Nterminal α-helix region; a hypervariable central region, and a semi-conserved C-terminal region containing β-strands. Pili binds buccal, tracheal and corneal epithelial cells, specifically through interaction with a disulfide-loop (DSL) region that is found at the C-terminus of the pilin monomer called the receptor-binding domain (RBD). This domain of P. aeruginosa pilin is a suitable candidate for a peptide vaccine (4) . The DSL region is structurally highly conserved among type IV pilins of all species of P. aeruginosa, although the size of the loop (from 12 to 31 amino acids in P. aeruginosa) and its sequence are varied among pilin alleles. The C-terminal DSL of the pilin subunit was shown by monoclonal antibodies that mediate attachment to epithelial cell receptors, this finding suggests that PilA itself acts as both a major structural subunit and an adhesin (7, 11) . There are several studies mentioning that the attachment of P. aeruginosa to the respiratory mucosa, skin, corneal T surfaces is multifactorial. P. aeruginosa type IV pili are thought to interact with the glycosphingolipid epithelial receptor asialo-GM1 (aGM1) via the DSL, which is proposed to be exposed only at the tip of pilus. The membrane distribution of asialo-GM1 is compared to that of caveolin-1 and understanding lipid partitioning between membrane domains (11, 12) . Finally, T4P from all strains of P. aeruginosa shares a common receptor. However, the sequence diversity presents a significant obstacle to the development of a broadly protective RBD-based vaccine targeting the T4P.
The pET-based vectors are the most powerful systems, yet developed for the cloning and expression of recombinant proteins in the E. coli.
One vector of this system, pET26b(+) (abbreviated as pET26b), was used in this study for the construction and expression of recombinant proteins. This expression vector is under the control of the T7 promoter and carries an N-terminal PelB signal sequence for potential periplasmic localization of recombinant protein and optional Cterminal His-tag sequence for detection and purification (13) . In the present study, we designed a chimeric plasmid that contains pilA region, which encodes the three peptides of DSL (in triplicate forms). The pilA region contains three domains, 
Construction of the expression vector
The pilA gene was inserted into the E. coli 
Expression and isolation of the recombinant protein
The expression and purification of the r-PilA protein was performed as previously described (14), with slight modification. The E. coli BL21 (DE3) was transformed with the plasmid pET26b/pilA. A single colony was grown overnight in 5 ml LB medium supplemented with kanamycin (30 µg/ml) Table 2 . The characteristics of the studied strains.
Host

Relevant characteristics E. coli BL21 (DE3)
Host strain for overexpression of the recombinant protein from the T7 promoter
E. coli Top10 Host strain for proliferation of the recombinant vector
Pseudomonas aeruginosa PAO1 common reference strain in laboratory, spontaneous chloramphenicolresistant mutant, non-mucoid strain (Thermo Scientific, USA) and Bradford protein assay using standard albumin (Sigma, USA) and finally aliquoted in 0.5 mg/ml vials.
Pseudomonas aeruginosa
Immunoblot analysis
The purified r-PilA was electrophoresed in a 
Opsonophagocytic killing assay (OPA)
The ability of antisera to opsonize P.
aeruginosa for killing in the presence of complement and macrophage was evaluated using an in vitro OPA as described previously (15) . 
Twitching inhibition test
To verify the functionality of the specific polyclonal antibody, the twitching inhibition assay was carried out according to Castric et al. (16) 
Statistical analysis
Data were analyzed by ANOVA or KruskalWallis test, depending on the assay. Differences were considered significant at p less than 0.05.
Statistical analysis was performed using the software GraphPad Prism version 6.0 for Windows, (GraphPad Software, San Diego, CA, USA).
Results
Construction of plasmid for periplasmic purification
To overcome the problems associated with cytoplasmic expression of the r-PilA protein, the plasmid pET26b was constructed for periplasmic expression of the protein. The coding sequence of tandem repeats of three pilA domains with specific linkers, was constructed in the pET26b expression Transformants were characterized by enzymatic digestion. The recombinant plasmid, pET26b/pilA, was extracted and its orientation confirmed by digestion with two restriction enzymes was mentioned above. The two expected bands were observed on gel: 649 and 5360 bp bands (Fig. 2) .
Sequence analysis of recombinant pET26b/pilA confirmed that there were no amplification errors and that construction was accurate. 
Expression and confirmation of the r-PilA
To construct an over-expression system, the coding 28 kDa in molecular weight (Fig. 3) . Furthermore, almost all the protein was present as soluble protein in the cell disruption supernatant. Western blot analysis on total cell extracts (induced and noninduced) and purified protein using anti His-tagspecific antibodies showed that the protein was substantially expressed using the pET26b/pilA expression vector when IPTG was added at the early-exponential phase of growth and after collecting the cells 2 h after induction (Fig. 4) . The checkerboard titration demonstrated that the optimal dilution of the anti r-PilA antibody to react with the r-PilA was 1:8. The yield of purified fusion protein was about 2.77 mg per liter of culture media. 5 . The opsonic killing activity of four different dilution of anti r-PilA antibody against P. aeruginosa strains PAO1and 6266E. To do this test, desired strains were incubated with different dilutions of mouse anti r-PilA antiserum and mouse macrophage in the presence of rabbit complement. The opsonic killing activity was observed when specific r-PilA antibody was treated with PAO1 and 6266E strains. No cross reaction was detected between NMS and the strains. Bars represent means of triplicate determinations, and error bar indicate SD. Results were accepted to be significant at P less than 0.05. The Asterisks represents the groups which were significantly different (P < 0.05) and ND represents non-detectable difference.
Fig 6.
Twitching inhibition of P. aeruginosa PA01 and 6266E strains in the presence of r-PilA antibody on motility agar (LB broth with 1% w/v agar). The motility agar plates supplemented with a 1:8 dilution of anti r-PilA antiserum or NMS were stab inoculated with P. aeruginosa and incubated for 18 h at 37 °C. The antiserum raised against r-PilA inhibited motility of P. aeruginosa strains PAO1 and 6266E (b and d, respectively) compared with NMS (a and c, respectively).
Opsonophagocytic killing activity
We next performed an opsonophagocytic assay to test whether the r-PilA-specific antibodies present in the immunized mice sera could mediate killing of P. aeruginosa PAO1 and 6266E strains by macrophages in the presence of complement.
Unlike the NMS, the sera from mice immunized with the r-PilA showed opsonophagocytic killing activity against PAO1 and 6266E strains, to some extent, so that the number of viable bacterial cells decreased over 17.5% and 16.3% respectively, after 90 min compared with the control group (Fig. 5) . In the presence of NMS, as the control group, no opsonic activity was observed. These data indicate that the anti r-PilA antibodies have a partial opsonic activity for killing of the P. aeruginosa strains.
Twitching inhibition assay
Immunized and non-immunized mouse sera were tested in the twitching inhibition assay to evaluate their functional activity for immobilization of P. aeruginosa strains PAO1 and 6266E. In this assay, NMS was used as control. As shown in Figure 6 , the r-PilA antibody was able to inhibit slightly the motility of the PAO1 strain at a dilution of 1:8. This antibody showed cross reactivity with 6266E strain as it slightly inhibited the motility of the strain. The two strains were motile in the presence of NMS.
Discussion
Pseudomonas aeruginosa is an opportunistic pathogen which is commonly considered as an infectious agent in immunocompromised hosts. In these patients, infections are often severe and lifethreatening. There is great interest in developing a vaccine to prevent P. aeruginosa infection, given that immunization is always considered the most economic and efficient means for such prevention, especially in developing countries. The selection of antigenic targets is critical in the design of a vaccine. It has been suggested that adhesins act as key roles in the initial stages of infection, where they allow the bacteria to anchor themselves to the epithelial layer, which can lead to successive colonization and potential invasion (17) . A large number of published data showed that pili might be the most definitive antigen candidate (18, 19) . T4P are essential virulence factors of P. aeruginosa that have been extensively studied in the mouse model (8, 20) . Because of its length, the T4P has been It is indicated that different routes of immunization could affect different levels of immune response (26) . In the present study, the mice immunization was performed via intranasal (i.n.) route. It has been well documented that in. delivery of vaccine has an appropriate influence on induction of mucosal (especially IgA response) and systemic immune reactions against respiratory pathogens. In addition, easy accessibility to nasal cavity, needle-free injection and low antigenic dose are some other advantages of in. immunization (27) .
In this work, a protocol was examined to express and purify the recombinant PilA protein in E. coli expression strain BL21 (DE3). Since the PilA protein contains at least 18 cysteine residues, it must be expressed as a secretory strategy; hence we 
